Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients
dc.contributor.author | Terpos, E. | en |
dc.contributor.author | Mougiou, A. | en |
dc.contributor.author | Kouraklis, A. | en |
dc.contributor.author | Chatzivassili, A. | en |
dc.contributor.author | Michalis, E. | en |
dc.contributor.author | Giannakoulas, N. | en |
dc.contributor.author | Manioudaki, E. | en |
dc.contributor.author | Lazaridou, A. | en |
dc.contributor.author | Bakaloudi, V. | en |
dc.contributor.author | Protopappa, M. | en |
dc.contributor.author | Liapi, D. | en |
dc.contributor.author | Grouzi, E. | en |
dc.contributor.author | Parharidou, A. | en |
dc.contributor.author | Symeonidis, A. | en |
dc.contributor.author | Kokkini, G. | en |
dc.contributor.author | Laoutaris, N. P. | en |
dc.contributor.author | Vaipoulos, G. | en |
dc.contributor.author | Anagnostopoulos, N. I. | en |
dc.contributor.author | Christakis, J. I. | en |
dc.contributor.author | Meletis, J. | en |
dc.contributor.author | Bourantas, K. L. | en |
dc.contributor.author | Zoumbos, N. C. | en |
dc.contributor.author | Yataganas, X. | en |
dc.contributor.author | Viniou, N. A. | en |
dc.date.accessioned | 2015-11-24T18:56:08Z | |
dc.date.available | 2015-11-24T18:56:08Z | |
dc.identifier.issn | 0007-1048 | - |
dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/18988 | |
dc.rights | Default Licence | - |
dc.subject | Aged | en |
dc.subject | Aged, 80 and over | en |
dc.subject | Anemia, Refractory/drug therapy | en |
dc.subject | Anemia, Refractory, with Excess of Blasts/drug therapy | en |
dc.subject | Anemia, Sideroblastic/drug therapy | en |
dc.subject | Erythropoietin/*therapeutic use | en |
dc.subject | Female | en |
dc.subject | Humans | en |
dc.subject | Male | en |
dc.subject | Middle Aged | en |
dc.subject | Myelodysplastic Syndromes/*drug therapy | en |
dc.subject | Prospective Studies | en |
dc.subject | Treatment Outcome | en |
dc.title | Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients | en |
heal.abstract | Treatment with recombinant human erythropoietin (rHuEpo) improves anaemia in approximately 20% of patients with myelodysplastic syndromes (MDS). We investigated the potential advantage of a prolonged administration of rHuEpo to achieve higher erythroid response rates (RR) in 281 MDS patients: 118 with refractory anaemia (RA), 77 with refractory anaemia and ringed sideroblasts (RARS), 59 with refractory anaemia with excess of blasts and blast count < 10% (RAEB-I), and 27 with RAEB and blast count between 11-20% (RAEB-II). rHuEpo was given subcutaneously at a dose of 150 U/kg thrice weekly, for a minimum of 26 weeks. Response to treatment was evaluated after 12 and 26 weeks of therapy. The overall RR was 45.1%; the RR for RA, RARS, RAEB-I and RAEB-II were 48.3%, 58.4%, 33.8% and 13% respectively. A significant increase in RR was observed at week 26 in RA, RARS and RAEB-I patients, as the response probability increased with treatment duration. The RR was higher in the good cytogenetic prognostic group and serum Epo level of > 150 U/l at baseline predicted for non-response. The median duration of response was 68 weeks and the overall risk of leukaemic transformation was 21.7%. These results suggest that prolonged administration of rHuEpo produces high and long-lasting erythroid RR in MDS patients with low blast counts, particularly in those with pretreatment serum Epo levels of < 150 U/l and good cytogenetic prognosis. | en |
heal.access | campus | - |
heal.fullTextAvailability | TRUE | - |
heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/12100145 | - |
heal.identifier.secondary | http://onlinelibrary.wiley.com/store/10.1046/j.1365-2141.2002.03583.x/asset/j.1365-2141.2002.03583.x.pdf?v=1&t=h2bovhm4&s=51979d8006fc82b691e365af91a69cf80b1f323d | - |
heal.journalName | Br J Haematol | en |
heal.journalType | peer-reviewed | - |
heal.language | en | - |
heal.publicationDate | 2002 | - |
heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
heal.type | journalArticle | - |
heal.type.el | Άρθρο Περιοδικού | el |
heal.type.en | Journal article | en |
Αρχεία
Φάκελος/Πακέτο αδειών
1 - 1 of 1
Φόρτωση...
- Ονομα:
- license.txt
- Μέγεθος:
- 1.74 KB
- Μορφότυπο:
- Item-specific license agreed upon to submission
- Περιγραφή: